Cartalax

Cartalax, also known by its amino acid sequence designation AED (Ala–Glu–Asp), is a short synthetic tripeptide bioregulator studied primarily for its effects on cellular regulation in cartilage, connective tissue, and age-associated biological processes. Composed of just three amino acids—alanine, glutamic acid, and aspartic acid—Cartalax belongs to the Khavinson short peptide bioregulator framework, a class of ultrashort peptides investigated extensively by Russian gerontologists for their capacity to modulate gene expression and restore tissue-specific cellular function.

The Khavinson bioregulator concept is based on the principle that short peptides, typically two to four amino acids in length, can interact directly with DNA and influence transcriptional regulation at nanomolar concentrations. Unlike conventional pharmacologic agents that act through receptor binding or enzyme inhibition, these peptides are theorized to function as endogenous regulatory signals that restore normal gene expression patterns disrupted by aging or pathological conditions.

Cartalax has been investigated for its role in gene expression modulation, cellular renewal, and tissue-specific signaling across multiple laboratory models. Research has focused on cartilage biology, chondrocyte proliferation, fibroblast function, renal tissue regeneration, and stem cell differentiation. All findings discussed in this article are derived from in vitro, ex vivo, and animal research. Cartalax is intended strictly for research use only and is not approved for diagnostic, therapeutic, or clinical use in humans.

How It Works

Cartalax exerts its biological effects through multiple interconnected mechanisms, all centered on the regulation of gene expression and intracellular signaling. Its ultrashort tripeptide structure allows efficient cellular penetration and direct interaction with intracellular targets without requiring carrier molecules or specialized transport systems.

Molecular Structure and Cellular Penetration

Cartalax is composed of three amino acids in sequence: alanine, glutamic acid, and aspartic acid. This minimal size and inherent polarity confer high biological accessibility in experimental systems. The tripeptide readily crosses cell membranes and reaches nuclear compartments, where it interacts with DNA-associated regions involved in transcriptional regulation. Research suggests that Cartalax engages in minor groove binding at specific nucleotide sequences, enabling it to act as a bioregulatory signal rather than a conventional pharmacologic agent. based on my experience and research.

Gene Expression Regulation

Multiple studies indicate that Cartalax influences the expression of genes associated with cellular proliferation, apoptosis regulation, extracellular matrix maintenance, and stress- and aging- related signaling pathways. These effects have been observed at nanomolar concentrations in controlled laboratory environments, consistent with the bioregulatory model in which ultrashort peptides serve as endogenous modulatory signals rather than high-dose pharmacologic interventions.

Modulation of Cellular Aging Pathways

Cartalax has been studied extensively in the context of cellular aging. Laboratory findings demonstrate modulation of genes and proteins central to the aging process, including cellular senescence markers such as p16, p21, and p53; longevity-related regulators such as sirtuins (notably SIRT-6); and growth and regeneration signaling pathways, including insulin-like growth factor 1 (IGF-1) expression. In mesenchymal stem cell cultures, Cartalax altered gene expression patterns differently depending on the aging model used, highlighting its role as a context-dependent regulatory peptide rather than a universal activator or inhibitor.

Extracellular Matrix Homeostasis

A key mechanism of Cartalax activity involves the modulation of enzymes responsible for extracellular matrix degradation, particularly matrix metalloproteinases (MMPs). By influencing MMP expression and activity, Cartalax helps maintain the structural integrity of connective tissues in experimental models. This mechanism is of particular relevance in cartilage biology, where extracellular matrix degradation is a hallmark of age-related degeneration.

DNA Interaction and Transcriptional Regulation

Research into the biophysical properties of Cartalax has demonstrated DNA-interactive properties linked to transcriptional regulation. The peptide’s ability to bind specific nucleotide sequences in the minor groove of DNA is believed to influence chromatin accessibility and gene transcription at targeted loci. This mechanism distinguishes Cartalax from conventional peptide therapeutics that act primarily through cell-surface receptor binding.

Research Benefits

Cartilage and Connective Tissue Biology

Cartalax has demonstrated the ability to stimulate chondrocyte proliferation in both young and aged animal models, reduce markers associated with programmed cell death under stress based on my experience and research. conditions, and modulate enzymes involved in extracellular matrix degradation. These findings have positioned Cartalax as a molecule of significant interest in osteoarticular research, particularly in models examining age-related cartilage decline and connective tissue degeneration.

Cellular Aging and Senescence

Through its modulation of senescence markers (p16, p21, p53) and longevity-associated regulators (SIRT-6), Cartalax has shown the capacity to influence cellular aging trajectories in laboratory models. Its effects on IGF-1 expression and related growth signaling pathways further support its role as a research tool for investigating the molecular mechanisms of aging and potential geroprotective strategies.

Fibroblast Function and Skin Cell Research

In dermal fibroblast studies, Cartalax demonstrated increased expression of proliferation markers such as Ki-67, reduced activity of apoptotic enzymes including caspase-3, and improved extracellular matrix homeostasis through modulation of collagen-related pathways. These effects have been investigated within the contexts of cellular aging and tissue regeneration research.

Renal Tissue Regeneration

Research exploring Cartalax activity in kidney tissue cultures found that the peptide increased cell renewal capacity in aged tissue samples, reduced expression of aging-associated molecular markers, and demonstrated DNA-interactive properties linked to transcriptional regulation. While mechanistically promising, these findings remain preclinical and exploratory.

Neurogenesis and Stem Cell Differentiation

Cartalax has been evaluated alongside other short peptides in stem cell differentiation research. In laboratory models, AED contributed to enhanced neuronal differentiation markers in stem cell cultures and altered lineage commitment signaling pathways. These observations support ongoing interest in Cartalax as a research tool for studying differentiation and cellular fate in regenerative biology.

What the Science Shows

The following summarizes key findings from the published scientific literature on Cartalax (AED). All studies cited are preclinical, involving in vitro, ex vivo, or animal models.

Linkova et al. (2016) — Skin Fibroblast Aging

based on my experience and research. This study investigated the effects of short peptides, including Cartalax, on the regulation of skin fibroblast functions during aging in vitro. Researchers found that Cartalax increased expression of the proliferation marker Ki-67, reduced activity of the apoptotic enzyme caspase-3, and improved extracellular matrix homeostasis in aged fibroblast cultures. These results suggest that Cartalax can modulate fibroblast behavior in ways relevant to understanding skin aging at the cellular level.

Khavinson et al. (2020) — Short Peptides and Skin Aging

This review examined the role of short peptides, including Cartalax, in the regulation of skin function during aging. The authors summarized evidence that ultrashort peptides can influence gene expression patterns in skin cells, modulate senescence-associated markers, and support cellular renewal processes. Cartalax was highlighted for its effects on fibroblast proliferation and extracellular matrix maintenance.

Khavinson et al. (2014) — Gerontological Research

Published in Advances in Gerontology, this study explored the broader gerontological applications of short peptide bioregulators. The research demonstrated that Cartalax and related peptides could modulate age-related changes in gene expression across multiple tissue types, with effects observed at low concentrations consistent with a bioregulatory rather than pharmacologic mechanism of action.

Chalisova et al. (2015) — Kidney Tissue Cultures

This study examined peptide regulation of cell renewal processes in kidney tissue cultures from young and old animals. Cartalax increased cell renewal capacity in aged kidney tissue samples and reduced expression of aging-associated molecular markers. The findings demonstrated tissue-specific activity consistent with the bioregulatory peptide model.

Ashapkin et al. (2020) — Mesenchymal Stem Cell Aging

Researchers evaluated the effects of short peptides on gene expression in human mesenchymal stem cell aging cultures. Cartalax altered expression patterns of genes associated with cellular senescence (p16, p21, p53), longevity regulation (SIRT-6), and growth signaling (IGF-1). Importantly, the peptide’s effects varied depending on the aging model used, reinforcing its characterization as a context-dependent modulator.

Caputi et al. (2019) — Neuronal Differentiation of Stem Cells This study assessed the effects of short peptides on neuronal differentiation of stem cells. Cartalax contributed to enhanced neuronal differentiation markers and altered lineage based on my experience and research. commitment signaling pathways in stem cell cultures. These findings suggest potential research applications in regenerative biology and developmental signaling.

Myakisheva et al. (2023) — Chondrocyte Proliferation and Geroprotection The most recent study in the Cartalax literature examined peptides of cartilage tissue with a focus on the regulation of chondrocyte proliferation and geroprotective properties. Cartalax stimulated chondrocyte proliferation in both young and aged models, reduced apoptotic markers, and modulated matrix metalloproteinase activity. The authors discussed prospects for use in osteoarthrosis research models.

Dosing Protocol

Cartalax is available as an oral capsule formulation and as a reconstitutable lyophilized powder for subcutaneous injection. Dosing information presented below is based on published research protocols, manufacturer guidelines, and community-reported usage patterns. No clinical trials have established definitive human dosing. All dosing information is provided for research reference only.

Oral Capsule Protocol

Phase Dose Frequency Duration Standard 1–2 capsules (typically 1–2 times daily 10–30 days 10–20 mg) Maintenance 1 capsule Once daily Repeat cycle after 3–6 month break

Oral capsule protocols are typically administered in cycles, with a course lasting 10 to 30 days followed by a rest period of three to six months before repeating. Capsules are generally taken 15 to 20 minutes before meals with water.

Injectable Protocol

When used in injectable form, Cartalax is reconstituted from lyophilized powder and administered via subcutaneous injection. Injectable protocols in research settings typically involve low microgram-range doses administered daily or every other day for a defined course period. Specific reconstitution volumes and concentrations should be determined based on the vial size and purity of the research-grade product obtained.

Application-Specific Considerations

based on my experience and research.

• Cartilage and Joint Research: Standard oral cycling protocol; some researchers

combine with other cartilage-targeted bioregulators such as Sigumir

• Anti-Aging and Geroprotection Research: Standard oral cycling protocol; often used

alongside other Khavinson bioregulators targeting complementary tissue systems

• Skin and Connective Tissue Research: Standard oral protocol; may be paired with skin-

targeted peptide bioregulators such as Vladonix or Endoluten

Reconstitution Instructions (Injectable Form) 1. Remove the plastic cap from the vial and wipe the rubber stopper with an alcohol swab. 2. Draw the appropriate volume of bacteriostatic water into a sterile syringe (refer to manufacturer’s instructions for the specific vial size). 3. Insert the needle through the rubber stopper at an angle. 4. Direct the stream of water down the inside wall of the vial slowly to avoid disturbing the lyophilized powder. 5. Allow the peptide to dissolve without shaking. Gentle swirling is acceptable. 6. Once fully dissolved, the solution should appear clear and colorless. 7. Label the vial with the date and concentration.

Side Effects

Cartalax has not been evaluated in controlled human clinical trials, and comprehensive side- effect data from human subjects are not available. The following information is based on preclinical research observations, manufacturer disclosures, and anecdotal community reports.

Reported Observations

• Generally well tolerated in laboratory and animal models at the concentrations studied
• No significant toxicity reported in published preclinical studies
• Ultrashort peptide structure minimizes the likelihood of immunogenic reactions
• Oral bioregulator formulations in the Khavinson class are generally reported to have

favorable tolerability profiles in observational use

Theoretical Concerns

• As a gene expression modulator, unpredictable effects on cellular pathways cannot be

excluded, particularly with prolonged or supraphysiologic dosing

based on my experience and research.

• Potential for individual hypersensitivity to peptide components or excipients in capsule

formulations

• Effects on extracellular matrix enzymes (matrix metalloproteinases) could theoretically

influence tissue remodeling in unintended ways

• Long-term safety data in humans are absent

Injectable-Specific Considerations

• Injection site irritation, redness, or mild discomfort (common to all subcutaneous peptide

injections)

• Risk of contamination or infection if sterile technique is not maintained
• Localized reactions may occur in sensitive individuals

Contraindications and Precautions

Individuals Who Should Avoid Cartalax

• Individuals with known hypersensitivity to any of the constituent amino acids (alanine,

glutamic acid, aspartic acid) or excipients

• Pregnant or breastfeeding women (no safety data available)
• Individuals with active malignancies or a history of cancer, given the peptide’s effects on

cellular proliferation and gene expression

• Children and adolescents (no pediatric safety or efficacy data)

Individuals Who Should Use with Caution

• Those with autoimmune disorders, as modulation of immune-related gene expression

pathways could theoretically influence disease activity

• Individuals taking immunosuppressive or immunomodulatory medications
• Those with chronic kidney disease, given the observed effects on renal tissue cultures
• Anyone on medications that affect extracellular matrix metabolism or connective tissue

remodeling

General Precautions

• Cartalax is intended for research use only and is not approved for human therapeutic

application

• No controlled human clinical trials have been conducted

based on my experience and research.

• All dosing information is extrapolated from preclinical research and should be interpreted

accordingly

• Individuals considering use should consult with a qualified healthcare professional

Comparison to Related Compounds

Cartalax belongs to the broader class of Khavinson short peptide bioregulators. The following table compares Cartalax with related peptides commonly encountered in the bioregulator research literature.

Compound Sequence Primary Target Key Activity Administration Cartalax (AED) Ala–Glu–Asp Cartilage, Chondrocyte Oral / Injectable connective tissue proliferation, anti- senescence Sigumir Multi-peptide Cartilage, bone Joint and bone Oral capsule complex tissue support Epithalon (AEDG) Ala–Glu–Asp–Gly Pineal gland, Telomerase Injectable telomeres activation, melatonin regulation Vesugen (KED) Lys–Glu–Asp Vascular tissue Endothelial Oral / Injectable regulation, vascular health Vilon (KE) Lys–Glu Immune system Immune Oral / Injectable modulation, thymic support

Cartalax vs. Sigumir

Both Cartalax and Sigumir target cartilage and joint tissue, but they differ in composition and mechanism. Cartalax is a defined tripeptide (AED) with documented gene expression effects at the molecular level. Sigumir is a multi-peptide complex derived from cartilage tissue, acting through a broader and less precisely characterized mechanism. Cartalax offers greater mechanistic specificity, while Sigumir provides a more complex multi-peptide signal.

Cartalax vs. Epithalon (AEDG) Cartalax (AED) and Epithalon (AEDG) share three of four amino acids and both belong to the Khavinson bioregulator family. However, their primary targets differ substantially. Epithalon is best known for its effects on telomerase activity and pineal gland function, whereas Cartalax is based on my experience and research. oriented toward cartilage biology, connective tissue maintenance, and cellular senescence modulation. The two are sometimes used in combination in multi-system anti-aging research protocols.

Success Tips

Follow Cycling Protocols

Khavinson bioregulators, including Cartalax, are generally designed for use in defined cycles rather than continuous administration. A standard course of 10 to 30 days followed by a rest period of three to six months is the conventional approach. Cycling is thought to allow the regulatory effects to integrate without overstimulation.

Combine Strategically

In the Khavinson bioregulator framework, peptides are often combined based on their tissue- specific targets. Cartalax may be paired with complementary bioregulators targeting vascular tissue (Vesugen), immune function (Vilon), or neuroendocrine regulation (Epithalon) for multi- system research protocols. However, each combination should be approached thoughtfully and based on the specific research objectives.

Administer on an Empty Stomach

For oral capsule formulations, administration 15 to 20 minutes before meals is generally recommended to optimize absorption. Capsules should be taken with water without crushing or opening them.

Maintain Consistency

Bioregulatory peptides exert their effects through cumulative gene expression modulation rather than acute pharmacologic action. Consistent daily dosing throughout the course period is important for achieving the intended regulatory effects.

Document and Monitor

Given the preclinical nature of the evidence base, researchers and individuals should maintain records of any observations, changes, or responses throughout the course period. Systematic documentation supports better evaluation of outcomes and informs future protocol decisions.

Foundation Matters

based on my experience and research. Bioregulatory peptides are not a substitute for foundational health practices. Adequate sleep, proper nutrition, regular physical activity, and stress management remain essential regardless of any research compound being investigated.

Storage and Handling

Oral Capsule Formulations

• Store at room temperature in a cool, dry place away from direct sunlight
• Keep in original packaging until use
• Protect from moisture and excessive heat
• Do not use beyond the expiration date indicated on the packaging

Lyophilized Powder (Injectable Form) — Before Reconstitution

• Store in the freezer at −20°C for long-term storage
• Refrigeration at 2°C to 8°C is acceptable for shorter-term storage
• Protect from light
• Stable for extended periods when properly frozen

After Reconstitution (Injectable Form)

• Refrigerate at 2°C to 8°C
• Use within two to three weeks for optimal potency
• Protect from light
• Do not freeze after reconstitution
• Discard if the solution becomes cloudy, discolored, or contains particulate matter

Legal Status

United States

Cartalax is not FDA approved for any diagnostic, therapeutic, or clinical indication. It is available as a research compound and is not approved for human use. Oral capsule formulations of Khavinson bioregulators are available through specialty suppliers but are not classified as approved drugs or dietary supplements under FDA regulation.

Russia and Former Soviet States

based on my experience and research. The Khavinson short peptide bioregulators, including Cartalax, were originally developed and studied within the Russian gerontological research tradition. Some formulations are available through specialized pharmacies and research suppliers in Russia and neighboring countries, though regulatory classifications vary.

International

Legal status varies by country. Cartalax is generally classified as a research compound or unregulated peptide in most jurisdictions. Users should verify the regulatory status applicable in their region before obtaining or using this compound.

Frequently Asked Questions

What is Cartalax used for in research?

Cartalax is used in research settings focused on cartilage and connective tissue biology, cellular aging and senescence models, gene expression and epigenetic regulation, chondrocyte and fibroblast proliferation studies, and stem cell differentiation. Its activity is best understood as regulatory and modulatory rather than pharmacologically stimulatory.

Is Cartalax the same as Epithalon?

No. Although Cartalax (AED) and Epithalon (AEDG) share three amino acids and both belong to the Khavinson bioregulator family, their primary targets and mechanisms differ. Epithalon is primarily associated with telomerase activation and pineal gland regulation, while Cartalax targets cartilage biology, connective tissue, and cellular senescence pathways.

How is Cartalax administered?

Cartalax is available in both oral capsule and injectable lyophilized powder formulations. Oral capsules are the most common form and are taken in defined cycles of 10 to 30 days. Injectable forms are reconstituted with bacteriostatic water and administered subcutaneously.

Are there human clinical trials for Cartalax?

No controlled human clinical trials have been published for Cartalax. All available evidence is derived from in vitro cell culture studies, ex vivo tissue experiments, and animal models. The absence of clinical trial data means that human efficacy and safety have not been formally established.

Can Cartalax be combined with other bioregulators?

based on my experience and research. In the Khavinson bioregulator framework, peptides are often combined based on their tissue- specific targets. Cartalax is commonly paired with other bioregulators such as Vesugen (vascular), Vilon (immune), or Epithalon (neuroendocrine) in multi-system research protocols. However, no clinical data exist to validate specific combination regimens.

How long does a typical Cartalax cycle last?

A standard oral capsule course typically lasts 10 to 30 days, followed by a rest period of three to six months before repeating. This cycling approach is consistent with the general Khavinson bioregulator protocol philosophy.

Does Cartalax have any known side effects?

No significant adverse effects have been reported in published preclinical studies. The ultrashort peptide structure minimizes the likelihood of immunogenic reactions. However, comprehensive human safety data are not available, and theoretical concerns related to gene expression modulation at supraphysiologic doses cannot be excluded.

References

8. Linkova N, Drobintseva A, Orlova O, Kuznetsova E, Polyakova V, Kvetnoy I, Khavinson V. Peptide Regulation of Skin Fibroblast Functions during Their Aging In Vitro. Bulletin of Experimental Biology and Medicine. 2016;161:175–178. 9. Khavinson V, Linkova N, Diatlova A, Gutop E, Orlova O. Short peptides: regulation of skin function during aging. Advances in Gerontology (Uspekhi Gerontologii). 2020;33(1):46–54. 10. Khavinson VKh, Tarnovskaia SI, Lin’kova NS, Poliakova VO, Durnova AO, Nichik TE, Kvetnoĭ IM, D’iakonov MM, Iakutseni PP. Advances in Gerontology (Uspekhi Gerontologii). 2014;27(4):651–656. 11. Chalisova NI, Lin’kova NS, Nichik TE, Ryzhak AP, Dudkov AV, Ryzhak GA. Peptide Regulation of Cells Renewal Processes in Kidney Tissue Cultures from Young and Old Animals. Bulletin of Experimental Biology and Medicine. 2015;159(1):124–127. 12. Ashapkin V, Khavinson V, Shilovsky G, Linkova N, Vanuyshin B. Gene expression in human mesenchymal stem cell aging cultures: modulation by short peptides. Molecular Biology Reports. 2020;47(6):4323–4329. 13. Caputi S, Trubiani O, Sinjari B, Trofimova S, Diomede F, Linkova N, Diatlova A, Khavinson V. Effect of short peptides on neuronal differentiation of stem cells. International Journal of Immunopathology and Pharmacology. 2019;33:2058738419828613. based on my experience and research. 14. Myakisheva S, Linkova N, Polyakova V, Ryzhak G. Peptides of Cartilage Tissue: Regulation of Chondrocyte Proliferation, Geroprotection and Prospects for Use in Osteoarthrosis. Vrach. 2023. doi:10.29296/25877305-2023-10-08.

based on my experience and research.